AbbVie’s quarterly results top estimates as newer drugs cushion Humira’s slide

AbbVie on Thursday reported second-quarter sales and profit that beat expectations as newer immunology drugs delivered the rapid growth needed to offset plunging sales of blockbuster Humira.

Previous post Dow’s stock dives as a weak economic recovery leads to rare earnings miss
Next post Tractor Supply Co.’s stock falls as sales fall short of estimates and shoppers rein in spending